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Functional imagingAbstract The aim of the work: To assess the perfusion CT characteristics of soft tissue tumors of
extremities and evaluate its feasibility as a functional imaging technique in detecting, characteriza-
tion, surgical planning and therapy monitoring of soft tissue tumors.
Patients & methods: 31 cases with soft tissue tumor of extremities underwent PCT. Patients were 20
males and 11 females; age ranged from 17 to 74 years, mean age was 47.3 years. The ﬁnal patholog-
ical results revealed three benign and 28 malignant soft tissue tumors, included 25 primary malig-
nant tumors and three secondary tumors (metastasis). All cases underwent ﬁrst-pass perfusion
imaging with a 64-detector row CT scanner. Perfusion (BF), peak enhancement intensity (PEI),
time to peak (TTP) and blood volume (BV) were measured in both tumor area and surrounding
normal muscles then statistically compared.
Results: Qualitative analysis of color-coded PCT maps efﬁciently differentiated areas of active
tumor/tumor residue from normal tissue. Quantitative analysis demonstrated that mean BF, PEI
and BV were signiﬁcantly higher in malignant tumors compared with surrounding healthy muscles
(p< 0.05), but mean value of TTP was not found to be statistically signiﬁcantly different. Receiver
operating characteristic (ROC) curve analysis showed that malignant tissue can be differentiated
well from normal muscle with BF greater than 12.9 ml/min/100 gm tissue, PEI higher than
22.8 HU or BV larger than 19.75 ml per 100 g tissue.
Conclusion: Preliminary results suggest a good value of PCT in detecting, characterization and
therapy monitoring of soft tissue tumors of extremities.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Background
An emerging aspect in cancer care is the individualized ap-
proach, in which the treatment strategies are targeted accord-
ing to tumor biology (35).
806 M.M. ElMaadawy et al.In the oncology ﬁeld, the process of developing new capil-
lary blood vessels resulting in tumor vascularization is known
as neoangiogenesis, which is integral to the growth and spread
of tumor, hence representing its biological aggressiveness. It
determines the ability of tumors to metastasize and predict
its response to treatment; highly vascularised tumors have been
shown to be associated with poor prognosis (2,22).
As multidetector CT (MDCT) is already established as a
modality of choice for tumor assessment and follow-up, proto-
col modiﬁcation to include functional analysis technique such
as Perfusion CT (PCT) seems attractive and fairly convenient
especially with the valuable physiological information ex-
tracted from it that could render an impact on patient manage-
ment (34). PCT displays and permits quantiﬁcation of the
abnormal microvasculature within tumors, thus allowing
assessment of aggressiveness (19).
Moreover, given that functional changes precede morpho-
logic changes after treatment, technique such as PCT allows
earlier assessment of tumor response to treatment than con-
ventional CT, which relies on tumor size (6). Morphology
has a lot of limitations, when you are following changes in vol-
ume of tumor; as it takes time for this change to become evi-
dent. Accordingly, PCT can be considered a surrogate
(indirect) imaging biomarker for biological aggressiveness
and treatment response especially to antiangiogenic drugs (36).
PCT has achieved great strides as a functional technique
since its inception in the oncology ﬁeld, with many potential
applications in brain tumors, head and neck tumors, lung can-
cer, colorectal carcinoma, hepatic and pancreatic malignancies
(30,37,26,24). To the best of our knowledge, no previous stud-
ies investigated the role of PCT in soft tissue tumors, which are
deﬁned as mesenchymal proliferations that occur in extra-skel-
etal non epithelial tissue of the body excluding viscera and
meninges, the vast majority of these tumors occur in lower
and upper extremities (32,44).
Soft tissue tumors are a large and heterogeneous group of
neoplasms. Traditionally, tumors have been classiﬁed accord-
ing to histopathologic features. Although most soft tissue tu-
mors of various histopathologic types are classiﬁed as either
benign or malignant, many are of an intermediate nature,Table 1 Summary of scan protocols for PCT technique.
Scanning parameters Perfusion scan
KVp 80–100
mAs 200–250
Gantry rotation 0.5 s
Table speed No increment
Scan type Volume acquisitio
Region scanned 4 cm
Slice thickness 5 mm
Matrix 512 · 512
Scan timing Test bolus
Image frequency Every 2 s for ﬁrst
Total scan time 60 s
Contrast Route I.V (via 16–18 gau
Dose 50 ml non ionic c
Concentration 370 mg/ml concen
Flow rate 4 ml/s
Radiation dose DLP = 34.6 mGy
E (eﬀective radiat
scanned body regwhich typically implies aggressive local behavior with a low
to moderate propensity to metastasize. Clinically, soft tissue
tumors are classiﬁed according to various parameters, includ-
ing location, growth pattern, likelihood of recurrence, presence
and distribution of metastases and prognosis (9,43).
This preliminary study was conducted to assess the perfu-
sion characteristics of soft tissue tumors of extremities and
evaluate the feasibility of PCT as a functional imaging tech-
nique in detecting, characterization, surgical planning and
therapy monitoring of soft tissue tumors.
2. Patients and methods
This study was conducted between October 2010 and May
2012 in the diagnostic radiology department of Mansoura
Oncology centre-Mansoura University located in Mansoura
city in Egypt, as a pilot study that was approved by our insti-
tutional review board.
It was designed as a prospective study (pilot proof of con-
cept) for 30 cases at least, within the speciﬁed time frame. A
consecutive series of adult patients who met the inclusion cri-
teria of having -proved or provisionally diagnosed- soft tissue
tumors and had no contraindication to a CT scan with con-
trast, have been asked to participate in this study.
Forty cases were enrolled in the study and had a PCT scan.
Nine patients were excluded from all analysis; due to contrast
extra-vasation in two patients, inability to obtain adequate
arterial time attenuation curve (TAC) in one patient, signiﬁ-
cant motion artifacts during the dynamic scan in three cases
and missed pathological ﬁnal diagnosis in three patients. The
ﬁnal study group included 31 cases.
2.1. PCT acquisition
CT acquisitions for CT perfusion were performed using a 64-
row-multi-slice CT scanner (Brilliance 64 CT scanner, Philips
Healthcare, Best Netherlands). Summary of scan protocol is
shown in Table 1.
Patient underwent a dynamic Perfusion CT scan that was
added to the routine requested CT scan which served as an
45 s then every 4 s for last 15 s. (25 images/slice)
ge cannula in anticubital vein)
ontrast medium
tration
*cm per one image.
ion dose) for perfusion scan ranged from 5.2 to 12.97 mSv acc. to
ion
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quested, a non-contrast CT scan was performed which served
as a localizer to determine the desired scanned region to be in-
cluded in the dynamic study. Low tube peak kiovoltage and
low tube current were used for the localizer scan (80 kVp
and 150 mAs) as well as thick sections (10 mm).
The dynamic study consisted of a scan covering a range of
40 mm (along Z-axis) obtaining parallel 5 mm-thick sections (8
slices). For masses larger than 4 cm, the dynamic perfusion
scan was centered on the levels that contained the largest
enhancing solid portions, which could be identiﬁed in cases
on whom an initial contrast CT study was performed. In other
cases, an initial non contrast CT scan was acquired and level of
interest was centered on levels with the largest tumor
dimensions.
A test bolus was used to accurately determine timing of
scan then images have been acquired every 2 s for the ﬁrst
45 s then every 4 s for 15 s yielding 25 images/slices that are
a total of 200 images for the 8 slices. Total scan time is 60 sFig. 1 PCT of soft tissue sarcoma in right shoulder. (a) Axial CT scan
tumor plane which appeared unrepresentative to tumor site. (c) Upon i
ﬁeld, the obtained arterial time attenuation curve was of inadequate
Apparently, severely attenuated artery diameter upon tumor compressiowhich cover the ﬁrst pass phase of contrast. The total dose
of contrast was 50 ml of non-ionic iodinated contrast agent
(Ultravist 370 mg/ml, Mallinckrodt Medical, Inc.) The rate
of injection was 4 ml/s. This was followed by 20 ml saline ﬂush
with the same rate of injection to keep the injection bolus tight
and prevent its retention in venous line. An automated power
injector and a 16/18 G ante-cubital cannula were used. They
were routinely warned to avoid motion if they feel a sudden
warm ﬂush at the site of injection.
2.2. PCT post processing
The ﬁrst fundamental step for calculation of perfusion param-
eters was to identify the input artery and insert manually a user
deﬁned region of interest (ROI) inside this artery so as to gen-
erate an arterial time attenuation curve (TAC). The arterial in-
put was manually inserted using a standardized circular ROI
(A) and the resultant arterial time attenuation curve was re-
viewed to insure the presence of a rapid rise to a high peak,image at level of tumor bulk. (b) Color-Coded map of BV at same
nserting ROI at input artery in the main artery within the scanned
shape, also value of peak arterial enhancement was low = 45.5.
n alters the perfusion scan. This case was excluded from the study.
808 M.M. ElMaadawy et al.followed by rapid descent of attenuation, and the absence of
early recirculation or other abnormalities in the shape of the
curve. One case was excluded from the study due to inability
to obtain an adequate TAC, apparently the severely attenuated
artery diameter upon tumor compression in this case alters the
perfusion scan (Figs. 1 and 4).
Dynamic CT images were reviewed in the cine-mode to in-
sure the absence of signiﬁcant motion artifacts. Motion artifact
was identiﬁed objectively by inserting a sample region of inter-
est (ROI) in the input artery at the ﬁrst image and reviewing its
position in all dynamic images. If the ROI failed to stay con-
ﬁned to the artery in all images, the study was excluded from
analysis. Three patients were excluded from the study due to
the presence of excessive motion artifacts.
Post processing color-coded perfusion parametric maps of
Blood Flow (BF), Peak enhanced intenisty (PEI), Time to peak
(TTP) and blood volume (BV) were automatically generated
using the Perfusion CT software where the Region of Interests
(ROIs) can be positioned in the tumor, and in all other parts of
the scanned volume. The acquired Perfusion CT parameter
values were demonstrated in (mL/100 g tissue/min) for BF,
149 (HU) for PEI, (s) for TTP and (mL/100 g tissue) for BV.
Every pixel of the images obtained is attributed a color
which represents a numeric value of the perfusion parameter
calculated for that pixel. The value of the perfusion parame-
ters, ranged from high (red) to low (blue).The color scale is
for each map was preset in order to maximize the differences
between areas with different perfusions.
2.3. PCT interpretation
Three circular ROIs were inserted in tumor bulk avoiding large
vessels, areas of necrosis and peri-tumoral tissue.Others circular
ROIs of same size were inserted in the normal surroundingmus-
cles or tissues. The software calculated numeric values for each
ROI correspond to the average BF, PEI, TTP and BV in this
ROI. The mean perfusion values for the tumor andmean values
for surrounding normalmuscleswere recorded for every patient.
2.4. PCT radiation dose
Calculated effective radiation dose exposure per scan using the
above parameters, for any affected region in the body, ranged
from 5.2 to 12.97 mSv (radiation dose from test bolus is in-
cluded). Effective radiation dose (E) was calculated using the
estimated dose-length product (DLP) – provided by the scan-
ner with each performed exam- to DLP conversion factor
according to scanned body region (38).
2.5. Statistical analysis
Statistical analysis of the data was done by using Statistical
Package for Social Science (SPSS) version 20.0 Qualitative
variables were presented as number and percent. Quantitative
variables were presented as mean ± SD. The Kolmogorov–
Smirnov (K–S) Test was done to test the normality of data dis-
tribution. Comparisons for parametric data were carried out
by unpaired t test for two different groups and analysis of var-
iance (ANOVA) for more than two groups with tukey post hocanalysis for inter group comparison. Comparisons for non
parametric data were carried out by Mann–Whitney for two
different groups and Kruskal–Wallis H test for more than
two groups with Wilcoxon multiple comparison test. Wilcoxon
matched-pair test was used to compare Perfusion CT parame-
ters between tumor and normal muscle.
Signiﬁcance was considered when p value <0.05. Bonfer-
roni correction was applied and p values were set at 0.05.
3. Result
Thirty-one cases with soft tissue tumor of extremities under-
went PCT. Patients were 20 males and 11 females; age ranged
from 17 to 74 years, mean age was 47.3 years. The ﬁnal path-
ological results revealed three benign and 28 malignant soft tis-
sue tumors, included 25 primary malignant tumors and three
secondary tumors (metastasis).
Malignant tumors were 21 de novo and four recurrent
malignancies, included 16 sarcomas, six carcinomas, three lym-
phomas and three metastasis (two renal cell carcinomas and
one round cell tumor).
3.1. Results of qualitative analyses of PCT maps
The perfusion maps of BF, PEI and BV showed higher perfu-
sion in malignant soft tissue tumors than the surrounding nor-
mal muscles, which enabled better tumor detection and
improved demarcation of tumor boundaries and inﬁltrated
muscles. Areas of viable tumor tissue were shown, which
should be targeted for biopsy.
On using qualitative map analysis for the detection of a sus-
pected tumor residue versus post-treatment changes; perfusion
maps – in one of the follow-up studies – have efﬁciently demon-
strated an area of active tumor residue of abnormal perfusion
compared to normal surrounding muscle perfusion (Fig. 2).
In another case, a suspicious area was conﬁrmed to be an area
of post operative changes and ﬁbrosis with no abnormal perfu-
sion identiﬁed on color-coded perfusion maps (Fig. 3).
Also, on using qualiﬁcation map analysis for comparison of
blood volume pre- and post- radiotherapy treatment in one
case, PCT map of BV showed a decrease in BV in the tumor
region despite the insigniﬁcant decrease in tumor size and pat-
tern of enhancement seen on routine axial post contrast CT
studies. This denotes a good response of intra-tumoral micro-
vasculature to radiotherapy manifested by decreased tumor
neoangiogenesis with a subsequent decrease in BV.
3.2. Result of quantitative analysis of PCT of malignant tumors
All sub-categories of malignant tumors had statistically signiﬁ-
cant higher parameters (BF,BVandPEI) in comparisonwith sur-
rounding normal muscle’s parameters (p values <0.05). For
TTP, it was of lower value inmalignant tumors compared to nor-
mal surroundingmuscles (Fig. 5), however it was not found to be
statistically signiﬁcantly different (p value = 0.357), results are
summarized in Table 2. On the other hand, benign tumors
showed no statistically signiﬁcant difference between any of tu-
mor parameters and surrounding normal muscles; p values (0.1,
0.32, 0.37 and 0.22) for (BF, PEI, TTP and BV, respectively).
Fig. 2 A 76 year old male follow up CT scan after sarcoma excision. Color-coded perfusion maps demonstrate areas of apparent high
perfusion (arrow) compared to surrounding musculature, which was proved to be malignant tumor residue after re-excision.
Perfusion CT: A biomarker for soft tissuetumors of extremities 809Results of Spearman’s rank correlation matrix test revealed
no signiﬁcant correlation between BF, PEI, MTT, BV and
pathological grade of malignant tumors (Grade I = 3 cases,
Grade II = 6 cases and Grade III = 16 in addition to three
cases of B cell lymphoma type). Also, no signiﬁcant correlation
identiﬁed between these parameters and T-staging. Lastly,
recurrent tumors (four sarcomas) showed no statistical signif-
icant difference for any of the parameters with those for de
novo sarcoma (12 sarcomas).
Receiver operating characteristic (ROC) curves were plot-
ted for each Perfusion CT parameter to test the accuracy asFig. 3 A 17 year old female follow-up scan following excision of a ra
for tumor residue was identiﬁed on post contrast CT study. (b) On
operative changes and ﬁbrosis similar to surrounding muscle (T2) pera means of diagnosis of malignancy. The area under the
ROC curve represents the overall accuracy. Threshold values
and their sensitivity and speciﬁcity were calculated. All curves
showed a igh diagnostic performance except for the TTP curve
(Fig. 6).
To differentiate malignant from normal tissue, threshold
levels of 12.9 ml/min/100 gm tissue for BF, 22.8 HU for
PEI and 19.75 ml per 100 g for BV were found to be suitable.
Table 3 shows sensitivity and speciﬁcity of each PCT param-
eter as a test for differentiation between malignant tumors
from normal surrounding muscles. The areas under thebdomyosarcoma of pelvic ﬂoor muscle. (a) A suspicious area (T1)
colored perfusion maps, it was conﬁrmed to be an area of post
fusion parameters with no abnormal colors identiﬁed.
Fig. 4 A 27 year old male with synovial sarcoma in anterior compartment of left thigh. (a) On axial CT image, ROIs were placed in four
sites within the main solid parts of the mass. Another ROI was placed in adjacent normal muscles. (b) Perfusion map of BV delineate
tumor boundaries, clearly demonstrated an area of different colors compared with other thigh muscles. (c) An adequate TAC for the ﬁrst
pass perfusion (60 s) demonstrated below the axial CT image. (d) The table shows four parameters for each ROI. Values are much higher
in tumor parts compared with those for normal muscle. Note that ROI (A1) inserted in a dominant artery in the scanned ﬁeld as the input
artery for calculation of perfusion parameters, peak arterial enhancement value shown above the table = 112.1.
810 M.M. ElMaadawy et al.ROC curves represent the diagnostic accuracy of each
parameter.
4. Discussion
Computed tomography is an imaging technique that continues
to beneﬁt from a great deal of technological progress. With the
evolution of MDCT, several approaches have been devised to
perform functional imaging to overcome the limitations of ana-
tomic imaging (37). Tumor PCT, with the acquisition of succes-
sive multiple phases, provides functional information to better
analyze microvasculature structure of soft tissue tumors. Tech-
nique can be readily incorporated into the existing CT proto-
cols that provide the main stay for imaging in oncology (31).
By capturing physiological information about tumor microvas-
culature; Perfusion CT can be a biomarker for tumor assess-
ment and therapy monitoring.Advantage of PCT over other functional imaging tech-
niques- like perfusion MRI- is that the functional analysis
of PCT is more reproducible than that of the MRI
(11,33). It provides valuable quantitative parameters that
are not easily acquired by MRI; these parameters could in-
crease efﬁciency in tumor grading, assessment of tumor bio-
logical aggressiveness, as well as assessment of tumor
response to therapy. In addition, absolute quantiﬁcation of
tumor perfusion using MRI is difﬁcult, because relation be-
tween signal intensity and gadolinium concentration is not
linearly related and needs more complicated methods of cal-
culations compared with the linear relation between iodine
concentration and tissue enhancement in PCT (11). Another
considerable functional imaging technique is the use of pos-
itron emission tomography (PET), however it is not widely
available and represents an extra step with substantial
expensive added cost (29).
Fig. 5 A 57 year old female with rhabdomyosarcoma in the arm. Table of perfusion parameters (below the color-coded map)
demonstrates that ROI (2) of signiﬁcant higher BF, PEI and BV values (74.9, 46.9 and 35.6) than corresponded parameters for normal
muscle at ROI (6) (5.1, 4.8 and 0.8, respectively). Also, TTP is of lower value at tumor region compared with that at normal muscle (16.3
comparing with 24.4 s, respectively). Note that ROI (5) shows 0.0 values for BV and BF, representing an area of cystic necrosis that
appears unenhanced on the axial CT image.
Perfusion CT: A biomarker for soft tissuetumors of extremities 811CT measurements of perfusion have been shown to be
reproducible and have been validated against a range of refer-
ence methods (5). The two most commonly used analytic
methods to estimate tissue perfusion from the dynamic CT
data are compartmental analysis and deconvolusion analysis
(31). Both modeling methods have been found to be generally
comparable, with differences in their theoretic assumption and
their susceptibility to noise (3).
This study has investigated the technique of Perfusion CT
in assessing soft tissue tumors, we used rapid dynamic acquisi-
tions focused on the ﬁrst pass of contrast material, as this early
phase seemed to be very important to the differentiation of
malignant from benign tissue (45). The post-processing tech-
nique in this study was based on compartmental method; it
estimates perfusion using the maximal slope (peak height) of
tissue concentration curve normalized to the arterial input
function (where perfusion is ratio of maximum slope of tissue
enhancement curve to maximum arterial enhancement). This
analytic method has the advantage of elimination recirculation
effect and needs short scan duration compared with other
methods, however it is more sensitive to image – noise and
needs scanning with higher mA (28).
The results in this study present preliminary evidence that
functional data of PCT – both qualitative and quantitative –
could be helpful tools in differentiating between viable tumor
tissues and surrounding normal muscles in soft tissue tumors.
In qualitative inspection of color-coded perfusion maps, we
found that areas of high perfusion within malignant tumorsdemonstrated differently from surrounding normal tissues
which enabled easier tumor detection and better demarcation
of tumor boundaries and extension. Color-coded perfusion
maps also clearly demonstrated areas of viable tumor tissue
with high perfusion colors that represent ideal targets for tissue
biopsy in contrast to necrotic areas (Fig. 5). These ﬁndings
were observed in previous studies; for example a study that
investigated CTP guided biopsy of pulmonary masses had re-
ported that CTP guided biopsy has the potential to improve
the accuracy of histopathological diagnosis with a lower risk
and higher achievement ratio (20).
In our study, identiﬁcation of area of high Perfusion colors
in a post-operative study had delineated tumor residue and
could differentiate it from post operative changes. This ﬁnding
demonstrated in several studies reported that viable tumors
tend to have high contrast-enhancement reﬂected in color scale
on parametric images (15), therefore the use of PCT as a sen-
sitive technique in the in vivo detection of tumor angiogenesis
can improve the identiﬁcation of residual tumor after therapy
or post operative on the basis that angiogenesis, and its phys-
iological imaging ﬁndings, can be used as a marker of viable
tumor (40).
Also, in post radiotherapy follow-up study in one of the
cases, color-coded perfusion maps were shown to be a beneﬁ-
cial tool to assess early tumor response that occurs in tumor
microvasculature structure, before apparent change in tumor
size or pattern of enhancement can be noted on post contrast
axial CT images. This is in agreement with studies demon-
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812 M.M. ElMaadawy et al.strated that conventional imaging strategies that use tumour
size or other structural criteria appear to be not suitable for
monitoring the effects of anti-angiogenic drugs (23,33).
As regards to quantitative analysis of PCT, an average of
three ROIs - inserted in enhanced parts of tumor- was used
rather than one single large ROI that include the whole tumor
area including the non enhanced necrotic parts. We hypothe-
sized that the enhanced parts of tumor are better reﬂecting
the process of angiogenesis, while poorly vascularised parts
represent necrosis. This hypothesizes based on several previous
studies that had correlated pattern of tumor enhancements
with mean vascular density (MVD) which is an immunohisto-
chemical method for evaluation of tumor angiogenisis (17).
Upon analysis of our data; signiﬁcantly higher BF, PEI and
BV values were observed in malignant soft tissue tumors com-
pared with co-responders in normal muscles (Fig. 7). For the
best of our knowledge no studies investigated Perfusion CT
on extremities’ soft tissue tumors, however our ﬁndings were
observed also in previous studies of Perfusion CT performed
on different body tumors outside the extremities soft tissue tu-
mors such as SCC of head and neck (8,42), colorectal carcino-
mas (10,21) and bronchial carcinomas (25,39).
Increased BF and BV in malignant tumors in general could
be attributed to the increased perfusion pressure and enlarged
neovascular bed as a consequence of tumoral neoangiogenesis,
as well as of increased intratumoral arteriovenous shunts
(19,8). This was demonstrated in a previous study that directly
compared PCT to histological mean vessel density where a sta-
tistically signiﬁcant correlation was reported between BF and
BV calculated by PCT on one hand and tumor microvessel
density as determined by histological immunostaining of
biopsy samples on the other (1).
Our result as regards to the fourth perfusion parameter
(TTP) unexpectedly showed no statistical signiﬁcant difference
between malignant tumor and normal surrounding muscle.
The study includes different subtypes of soft tissue tumors
with different tissue structures, for this reason it can be sup-
posed that some parameters such as (TTP) did not show the
expected predictive power in contrary to results of other stud-
ies that investigated speciﬁc tumor type such as brain gliomas
(4,7,14). However, a study compared between malignant and
benign pulmonary nodules demonstrated similar results to
our study and showed no statistical signiﬁcant differences in
TTP values between the two groups (all p> 0.05) (25).
Standard deviation in our data was high, probably reﬂect-
ing the high heterogeneity of tumor tissues and the wide range
of soft tissue tumor types. Various pathological subcategories
of malignant soft tissue tumors included in this study surely
decrease the average values of BF, BV and PEI. Also, the
majority of investigated tumors appear spatially inhomoge-
neous, with areas of vascular proliferation and other areas
of necrosis.
In our study, there was no signiﬁcant correlation between
perfusion values of soft tissue tumor and tumor grade. Also,
we did not ﬁnd any signiﬁcant correlation between tumor stage
and perfusion parameters as well. In a study done by (21) they
conclude that BF and MTT measurement by perfusion CT is
effective in predicting moderately differentiated colorectal car-
cinomas (CRCs), however it was limited in distinguishing well
differentiated and poorly differentiated CRCs.
Benign cases demonstrated much lower BFand BV values
compared with majority of malignant tumors, however small
Fig. 6 Receiver operating characteristic (ROC) curves for each PCT parameter as a test for differentiation between malignant soft tissue
tumors and normal muscles. Curves (a), (b) and (d) are for BF, PEI and BV, respectively, show a high diagnostic performance, while curve
(c) is TTP curve shows a low diagnostic performance (statistically was insigniﬁcantly different). The more the curve is higher and shifted to
the left denoting higher sensitivity and speciﬁcity.
Fig. 7 A 50 year old male with pleomorphic malignant ﬁbrous histocytoma of the left thigh. (a) Color-coded perfusion map of BV shows
an area of abnormal high perfusion delineating extent of tumor. (b) Table of perfusion parameters, shows four parameters (BF, PEI, TTP
and BV) for ROIs (1, 2, 3) in the tumor region, while ROI (4) inserted in adjacent normal muscle. In this case, parameter values of tumor
are much higher than those for normal muscle, including the TTP which was expected to be lower than normal muscle.
Perfusion CT: A biomarker for soft tissuetumors of extremities 813number of benign cases (three cases) did not allow to statisti-
cally correlate the parameters between the two groups.
PCT of soft tissue tumors is a feasible technique as demon-
strated in this study, except for cases where tumor exert signif-
icant compression and stenosis on the related artery in the
scanned region, resulting in inability to obtain adequate arte-
rial time attenuation curve hence calculation of perfusion
parameters was not feasible. We had only one case with such
signiﬁcant arterial stenosis, which was not surprising as bone
and soft tissue tumors in extremities tend to displace and en-
case rather than occlude the related vessels as mentioned by
(41). Another three cases in this study were excluded as they
had suffered from signiﬁcant motion artifacts which affect
the homogeneity of the arterial curve hence accuracy of
parameter values. Those tumors were located in the distal part
of extremities (one mass in the dorsum of the foot and two inthe legs), these regions seem to be more liable to subtle move-
ments which could be a possible factor for motion artifacts,
especially with relatively long (60 s) acquisition time on
scanned region.
The radiation burden associated with Perfusion study
determined mainly by number of images in the sequences
and tube current. Mettler et al. and Kalra et al. (27,18) stated
that; the designs of single slice and multi-slice scanners are sim-
ilar in most aspects that affect radiation dose, but multi-slice
scanning can potentially result in higher radiation risk to the
patient due to increased capabilities allowing long scan lengths
at high tube currents.
Several approaches to estimate effective dose for CT exams
have been investigated. A generic method was proposed to
estimate effective dose from the DLP of an exam (16), with
the DLP being reported on most systems. Conversion factors
Table 3 Diagnostic characteristics of perfusion parameters as a test for differentiation of malignant tumor from normal muscle.
Perfusion CT parameter Area under the curve Cutoﬀ threshold Sensitivity (%) Speciﬁcity (%)
BF (perfusion) 0.864 12.9 ml/min/100 g tissue 88.2 93
PEI 0.898 22.8 HU 91.2 100
TTP 0.456 41.3 s 70.6 67.7
BV 0.897 19.75 ml/100 g 91.2 96.7
814 M.M. ElMaadawy et al.for normalized effective dose per DLP were obtained from
Monte Carlo calculations of effective dose for various clinical
exams. These conversion factors depend only on the region of
the body being scanned (head, neck, thorax, abdomen, or pel-
vis). Usually this method is sufﬁciently exact for getting an
estimate on the total exposure that is also comparable with
other sources of radiation (13).
In this study, computed effective dose values were low as a
result of using low mA values, minimizing the scan length to
4 cm and limiting scan time to ﬁrst pass perfusion (ﬁrst 60 s).
Accordingly, effective radiation dose in this study had ranged
from 5.2 up to 12.5 mSv, which is approximately similar to the
same amount a person would receive naturally while living in
north America for approximately 2.5 years, and considered to
be a minimal risk according to the National Council on Radi-
ation Protection and Measurements (NCRP) and the US Food
and Drug Administration (FDA) which state that ‘‘risk of
developing fatal cancer anywhere in the body in twenty years
time for exposure to 10 mSv of radiation dose is less than 1
in 2,000 which is considered a minimal risk’’ http://www.fda.-
gov (12).
Moreover, in the context of oncology, radiation exposure
associated with perfusion CT is small compared with the
radiotherapy dose that many of these patients will receive.
However, Miles et al. addressed the need of guidelines for
PCT scan to alleviate the current confusion surrounding the
technique and help solve many questions that remain about re-
lated dose exposure.
There were some limitations to our study. First, the study
sample size was relatively small considering the wide variety
of soft tissue tumor subtypes. Accordingly, a study with a lar-
ger number of patients is needed. Second, we did not perform a
validation study, CT perfusion parameters were not compared
with the more established markers of angiogenesis, such as
microvessel density (MVD) or intratumoral interstitial
pressure.
5. Conclusion
To conclude, Perfusion CT is strengthening its role as a func-
tional imaging tool in the oncology ﬁeld in detection, charac-
terization and therapy monitoring of soft tissue tumors,
particularly as a biomarker of the biological aggressiveness
and treatment response of malignant tumors. It enables func-
tional imaging by both qualitative and quantitative assessment
of intra-tumoral microvascular structure.
Preliminary results in this study suggest the promising role
of Perfusion CT in detection, characterization and therapy
monitoring of soft tissue tumors of extremities especially that
PCT could be easily integrated into pre-existing clinical CT
protocols for oncology patients. Results also suggest a good
value of PCT in differentiating post- operative/post- therapeu-
tic changes from tumor residue or recurrence. Other beneﬁts ofPCT include better demarcation of tumor boundaries and
extensions as well as determination of the viable tumor por-
tions as targets for imaging-guided biopsy.
Further large population studies are recommended for bet-
ter statistical correlation of perfusion parameters with the wide
variety of soft tissue tumor sub-categories, as well as with
grading and staging.Conﬂict of interest
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